Trial Profile
Front-Line Treatment of Philadelphia Positive (Ph Pos), BCRABL Positive, Chronic Myeloid Leukemia (CML) With Two Tyrosine Kinase Inhibitors (TKI) (Nilotinib and Imotinib) A Phase II Exploratory Multicentric Centre.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2022
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 04 Dec 2018 Results comparing the prognostic value of ELTS and Sokal scores in a cohort of CML patients treated frontline with tyrosine kinase inhibitors presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Results (n=345) analysing prognostic value of BCR-ABL1 transcript type in chronic myeloid leukemia patients treated with Nilotinib from NCT00481052, NCT00769327 and NCT01535391 studies, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.